Legend Biotech (LEGN) sets interim CEO compensation terms

Rhea-AI Filing Summary

Legend Biotech Corporation has set specific compensation terms for Interim Chief Executive Officer Alan Bash, who was appointed effective July 24, 2026. The board’s compensation committee approved cash pay at a bi-weekly rate of $12,019, effective July 27, 2026, for as long as he serves in this interim role. This cash compensation is in addition to the pay he already receives as President of the CARVYKTI Business Unit.

The committee also approved a one-time grant of restricted stock units valued at $50,000 on the August 14, 2026 grant date. These RSUs vest over a three-year period, with one-third vesting on each of the first, second and third anniversaries of July 27, 2026, subject to his continued service. Legend Biotech states that this information is incorporated by reference into its existing registration statements on Form F-3 and Form S-8.

Key Figures

Interim CEO bi-weekly cash compensation: $12,019 One-time RSU grant value: $50,000 Vesting period for RSUs: three-year period +1 more

4 metrics

Interim CEO bi-weekly cash compensation $12,019 Bi-weekly rate for Alan Bash as Interim CEO, effective July 27, 2026

One-time RSU grant value $50,000 Restricted stock unit grant to Alan Bash on August 14, 2026

Vesting period for RSUs three-year period RSUs vest in three equal annual installments from July 27, 2026

Annual RSU vesting fraction one-third (1/3) Portion of RSUs vesting on each of the first, second and third anniversaries of July 27, 2026

Key Terms

restricted stock units, interim principal executive officer, incorporated by reference, registration statements

4 terms

restricted stock units financial

"a one-time grant of restricted stock units to Mr. Bash"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

interim principal executive officer regulatory

"designated him as the Company’s interim principal executive officer"

incorporated by reference regulatory

"is hereby incorporated herein by reference in the registration statements"

registration statements regulatory

"incorporated by reference in the registration statements on Form F-3 and Form S-8"

Registration statements are detailed documents companies file with securities regulators when they plan to offer shares or other securities to the public. They act like a recipe and instruction manual, listing a company’s business, finances, management, risks and how the offering will work, so investors can judge value and potential downsides. For investors, these filings provide the official, legally required facts needed to make informed decisions and spot warning signs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/06/2026 - 04:07 PM Accepted by SEC EDGAR 08/06/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What compensation will interim CEO Alan Bash receive at Legend Biotech (LEGN)?

Legend Biotech will pay interim CEO Alan Bash $12,019 bi-weekly and grant him $50,000 in RSUs. The cash pay starts July 27, 2026, and the RSUs are granted August 14, 2026, in connection with his interim CEO role.

How are the RSUs for Legend Biotech (LEGN) interim CEO Alan Bash structured?

Alan Bash’s RSUs have a grant-date value of $50,000 and vest over a three-year period. One-third vests on each of the first, second and third anniversaries of July 27, 2026, contingent on his continued service with Legend Biotech.

When does interim CEO compensation for Alan Bash at Legend Biotech (LEGN) become effective?

Alan Bash’s interim CEO cash compensation becomes effective July 27, 2026, following his appointment effective July 24, 2026. The RSU grant associated with this role is scheduled for August 14, 2026, with vesting measured from July 27, 2026.

Is Alan Bash’s interim CEO pay at Legend Biotech (LEGN) in addition to his existing role?

Yes. Legend Biotech states the $12,019 bi-weekly interim CEO cash compensation is in addition to the compensation Alan Bash receives as President of the CARVYKTI Business Unit, meaning he is compensated separately for his two responsibilities.

How does this interim CEO compensation relate to Legend Biotech (LEGN) registration statements?

Legend Biotech indicates this compensation disclosure is incorporated by reference into its registration statements on Form F-3 and Form S-8. This allows the same information to be treated as part of those existing securities registration documents.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: August 6, 2026

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

77 Corporate Drive

Bridgewater, New Jersey 08807

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Interim Chief Executive Officer Compensation

As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 27, 2026, on July 23, 2026, the Board of Directors (the “Board”) of Legend Biotech Corporation (the “Company”) appointed Alan Bash as the Company’s Interim Chief Executive Officer and designated him as the Company’s interim principal executive officer, each effective as of July 24, 2026.

In connection with his appointment as Interim Chief Executive Officer, the Compensation Committee (the “Compensation Committee”) of the Board has approved cash compensation for Mr. Bash at a bi-weekly rate of $12,019, payable with each bi-weekly paycheck for so long as he serves in that capacity, effective July 27, 2026. This compensation is in addition to the compensation Mr. Bash receives in his role as President of the CARVYKTI Business Unit. In addition, the Compensation Committee approved a one-time grant of restricted stock units (the “RSUs”) to Mr. Bash having a value equal $50,000 on the grant date of August 14, 2026. The RSUs shall vest over a three-year period with one-third (1/3) of the RSUs vesting on each of the one-year, two-year and three-year anniversaries of July 27, 2026, subject to the recipient continuing to provide services to the Company as of such date.

This report on Form 6-K is hereby incorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050 and 333-257625) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

				LEGEND BIOTECH CORPORATION (Registrant)
August 6, 2026				By:		/s/ Carlos Santos Garcia
						Carlos Santos Garcia
						Chief Financial Officer